CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.
The Joint United Nations Program on HIV-1/AIDS (UNAIDS) announced its goal to stop HIV-1 transmission by antiviral (HAART) treatment of patients since at the end of 2003 the number of people living with HIV-1 was 38 million, 25 million in the sub-Saharan region of Africa. The present review deals with a new approach to simultaneously treat HIV-1/AIDS patients in HIV-1 endemic regions with CpG oligodeoxynucleotides (ODNs) and people at high risk of infection with a vaccine containing CpG ODNs combined with synthetic HIV-1 peptides by intranasal and intradermal applications. During HIV-1 infection a gradual increase in the levels of IL-4 and IgE in the patients' serum, was reported. It was suggested that such an increase of the cytokine IL-4 and the IgE immunoglobulin are interconnected and may serve as indicators for the coming stage of AIDS. It was also suggested that the IL-4 and IgE increase in the serum of HIV-1 infected people resemble the increase of IL-4 and IgE levels in allergic patients that were exposed to endogenous or environmental allergens [Becker, Virus Genes 28, 5--18, 2004]. Indeed, it was reported that the HIV-1 virions' shed gp120 molecules, which contain a superantigen (superallergen) domain that enables the viral glycoprotein to bind the V(H)3 domain of IgE molecules that are bound to FcepsilonRI+ hematopoietic cells [basophils, mast cells, dendritic cells (DCs) and plasmacytoid DCs (pDCs)]. Such interaction was reported to induce the hematopoietic cells to release large amounts of Th2 cytokines IL-4, IL-5, IL-10 and IL-13. These findings led to the hypothesis [Op. cit.] that the cure of HIV-1/AIDS patients requires the induction of endogenous synthesis of type I interferons (INF alpha and beta) with a bacterial CpG rich DNA that will induce the patients' pDCs to release large amounts of type I IFNs. Under these conditions HIV-1 replication in polarized to Th2 cells is inhibited. Type I IFNs reactivate the patients' inhibited Th1 cells to synthesize IL-2 and IL-12 cytokines that activate the maturation of CTL precursors. The unmethylated bacterial DNA activates B synthesis to switch to IgG and IgA synthesis. The novel drug CpG ODNs is being tested for the prevention and the treatment of allergic humans and in the experimental system of allergic mice. It was also reported that treatment of mice with CpG ODN prior to or after retrovirus infections protected and cured, respectively, the retrovirus infection. It was also reported that CpG ODNs treatments of mice exposed to allergen protected them against the development of the allergic response. Phase I treatment of healthy people with CpG ODNs provided information on the safety of these compounds. The CpG ODNs A and B bind to Toll like receptors that are present in pDCs and B cells, respectively, CpG ODN - A is the ligand for TLR9+ pDCs and induce the release of large amounts of IFN-alpha, beta. CpG ODN-B is the ligand for TLR9+ in B cells and induce the synthesis of IgG and IgA. CpG ODN-C contains motifs from CpG ODNs A and B and is more active. The present review is based on findings from studies that reported that CpG ODNs treatment of retrovirus infected mice, monkeys and allergic mice prevented the virus and allergens caused diseases, respectively. Based on these studies, a hypothesis is presented that treatment of HIV-1 infected and AIDS patients with CpG ODN-A and B or CpG ODN-C have the potential to inhibit IL-4 synthesis and release from FcrepsilonRI+ hematopoietic cells by inducing TLR9+ pDCs to release large amounts of type I IFNs. TLR9+ B cells are induced by CpG ODN-B to switch from IgE to IgG, IgA synthesis. In addition, type I IFNs (alpha, beta) have the capacity to inhibit HIV-1 replication in polarized Th2 cells. Type I IFNs reactivate the patients' Th1 cells to synthesize IL-2 and IL-12 cytokines, activators of the precursor cytotoxic T cells (CTLs), leading to the reactivation of the inhibited adaptive immune response. Antiviral CTLs have the ability to clear the virus infection. The present novel approach to the treatment and of HIV-1/AIDS patients with CpG ODNs may prevent HIV-1 transmission and the AIDS pandemic if controlled studies on the treatments with CpG ODNs of HIV-1 infected people will be done by international and private agencies and companies to define the effective treatment regime and the efficacy of the treatments to HIV-1 infected people at different times post-infection. It is also hypothesized that in order to stop HIV-1 transmission in HIV-1 endemic regions the people at high risk of HIV-1 infection should be treated at the same time as HIV-1 infected people with a vaccine containing synthetic CpG-ODNs combined with synthetic HIV-1 peptides, compatible with the major HLA haplotypes of the regional population. The vaccine may be self-applied by people at high risk of infection by the intra-nasal route and by intra-dermal application as a "peplotion vaccine". The stimulation of the antiviral CTL response by HIV-1 infected people and the active antiviral immune response in the vaccinated population may lead to a decline in HIV-1 transmission and may be a model for control of the HIV-1/AIDS pandemic.
Becker
Yechiel
Y
Department of Molecular Virology, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. becker@md.huji.ac.il
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D016207:Cytokines / Q000097:blood; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control / Q000635:transmission; D015497:HIV-1; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy; D007073:Immunoglobulin E / Q000097:blood; D008562:Membrane Glycoproteins / Q000276:immunology; D051379:Mice; D018448:Models, Immunological; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use*; D011956:Receptors, Cell Surface / Q000276:immunology; D012307:Risk Factors; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D051217:Toll-Like Receptor 9; D051193:Toll-Like Receptors
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D016207:Cytokines; D008562:Membrane Glycoproteins; D009838:Oligodeoxyribonucleotides; D011956:Receptors, Cell Surface; C495371:TLR9 protein, human; D051217:Toll-Like Receptor 9; D051193:Toll-Like Receptors; D007073:Immunoglobulin E
Clin Exp Immunol. 2003 Aug;133(2):227-32
12869028
Eur J Immunol. 2001 Jul;31(7):2154-63
11449369
Vaccine. 2003 Jun 2;21(19-20):2461-7
12744879
Eur J Immunol. 2001 Oct;31(10):3026-37
11592079
Clin Immunol. 2003 Oct;109(1):64-71
14585277
Curr Med Chem. 2003 Aug;10(15):1423-39
12871139
Virus Genes. 2004 Jan;28(1):5-18
14739648
Nat Med. 2003 Jul;9(7):874-80
12835708
Curr Opin Microbiol. 2003 Oct;6(5):472-7
14572539
Semin Immunol. 2004 Feb;16(1):17-22
14751759
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14303-8
14610275
AIDS. 2004 Apr 30;18(7):1003-8
15096802
Semin Immunol. 2004 Feb;16(1):27-34
14751761
J Leukoc Biol. 2001 Jul;70(1):103-12
11435492
Virus Genes. 2004 Aug;29(1):147-65
15215692
Curr Opin Immunol. 2002 Oct;14(5):644-51
12183167
J Immunol. 2004 Jul 15;173(2):1219-23
15240713
Science. 2003 Jun 6;300(5625):1527-8
12791978
J Leukoc Biol. 2003 Jun;73(6):781-92
12773511
Nat Rev Immunol. 2004 Apr;4(4):249-58
15057783
Immunol Today. 1996 Mar;17(3):138-46
8820272
J Leukoc Biol. 2000 Oct;68(4):455-63
11037965
J Allergy Clin Immunol. 2002 Nov;110(5):706-12
12417878
Hum Immunol. 2002 Dec;63(12):1111-9
12480254
Virus Genes. 1995;10(3):227-37
8560784
J Immunol. 1986 Apr 1;136(7):2348-57
2419430
Vet Immunol Immunopathol. 2003 Jan 10;91(1):1-12
12507844
Clin Immunol Immunopathol. 1983 Jun;27(3):315-25
6223758
J Immunol. 2003 May 1;170(9):4717-23
12707351
Vaccine. 2002 Jul 26;20(23-24):2857-65
12126895
J Immunol. 2003 Oct 15;171(8):4320-8
14530357
Science. 1999 Jun 11;284(5421):1835-7
10364556
Adv Exp Med Biol. 1996;397:97-104
8718588
Altern Med Rev. 2003 Aug;8(3):223-46
12946237
Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8852-5
1528902
J Allergy Clin Immunol. 2000 Jul;106(1 Pt 1):124-34
10887315
J Immunol. 2000 Nov 15;165(10):5472-9
11067899
Drugs R D. 2003;4(4):249-53
12848591
J Infect Dis. 2002 Oct 15;186(8):1098-105
12355360
Immunol Today. 1993 Mar;14(3):107-11
8096699
J Immunol. 1998 Mar 15;160(6):2555-9
9510150
J Immunol. 2003 Oct 15;171(8):4028-39
14530323
Mol Cell Biol. 1998 Nov;18(11):6538-47
9774669
Clin Chem Lab Med. 1999 Mar;37(3):199-204
10353461
Eur J Immunol. 2003 Jun;33(6):1633-41
12778481
Eur J Immunol. 2004 Jan;34(1):251-62
14971051
Science. 2004 Sep 10;305(5690):1545-7
15361591
Virus Genes. 2004 Apr;28(3):319-31
15266113
J Immunol. 2004 Jul 15;173(2):1179-83
15240708
J Virol. 2002 Sep;76(18):9011-23
12186885
J Immunol. 2004 Aug 1;173(3):1647-57
15265893
Annu Rev Immunol. 1989;7:145-73
2523712
Semin Immunol. 2004 Feb;16(1):3-9
14751757
J Virol. 2003 Oct;77(19):10658-62
12970451
J Gen Virol. 2004 Jun;85(Pt 6):1533-1543
15166437
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9237-42
11470918
Vaccine. 2001 Apr 6;19(20-22):2862-77
11282197
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3972-7
8633000
J Immunol. 2003 Apr 1;170(7):3898-905
12646659
Am J Physiol Lung Cell Mol Physiol. 2003 Nov;285(5):L1137-46
12857672
J Biol Chem. 2004 May 21;279(21):21897-902
15016800
AIDS Patient Care STDS. 2003 Feb;17(2):47-51
12650142
Immunol Rev. 2001 Feb;179:102-18
11292014
J Immunol. 2001 Feb 15;166(4):2372-7
11160295
J Virol. 2002 Nov;76(22):11397-404
12388700
J Exp Med. 1997 Nov 17;186(10):1623-31
9362523
BMC Immunol. 2003 Jul 30;4:8
12887736
J Allergy Clin Immunol. 2001 Sep;108(3):417-23
11544462
Trends Immunol. 2004 Jul;25(7):381-6
15207506